Rethink ADHD Symptom Control™

Announcing the First Nonstimulant Approved for Adult ADHD in 20 Years¹

Qelbree™ (viloxazine extended-release capsules) logo with dosing information

Qelbree is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

Tuesday, June 14, 2022

**Faculty**
Greg Mattingly, MD Associate Clinical Professor Washington University School of Medicine President Elect, The American Professional Society of ADHD and Related Disorders (APSARD) President, Midwest Research Group St Louis, MO	Theresa R. Cerulli, MD Medical Director Cerulli and Associates North Andover, MA Lecturer/Clinical Supervisor Beth Israel Deaconess Medical Center Boston, MA	Andrew Cutler, MD Clinical Associate Professor of Psychiatry SUNY Upstate Medical University Chief Medical Officer Neuroscience Education Institute Lakewood Ranch, FL

Find a live venue near you

Please enter in your zip code.

Can’t make it to a live event?

Link in to participate via the live webcast.

Greg Mattingly, MD

Associate Clinical Professor,
Washington University
President, Midwest
Research Group
Board of Directors, APSARD
Editorial Board, Journal of
Attention Disorders

Ann Childress, MD

President
Center for Psychiatry and
Behavioral Medicine, Inc
Las Vegas, NV

Andrew J. Cutler, MD

Associate Clinical Professor
SUNY Upstate Medical University
Lakewood Ranch, FL

For US Healthcare Professionals Only

Qelbree™ (viloxazine extended-release capsules) logo

IMPORTANT SAFETY INFORMATION (CONT'D)
CONTRAINDICATIONS

• Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of
hypertensive crisis
• Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS

• Suicidal thoughts and behaviors: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during
the initial few months of drug therapy, and at times of dosage changes
• Heart rate, blood pressure increases: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following
increases in dosage, and periodically during therapy
• Activation of mania or hypomania: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree,
screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of
suicide, bipolar disorder, and depression
• Somnolence and fatigue: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential
somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree

ADVERSE REACTIONS
The most common adverse reactions (≥ 5% and at least twice the rate of placebo for any dose) in patients 6 to 17 years were somnolence, decreased appetite, fatigue,
nausea, vomiting, insomnia, and irritability, and in adults, insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation.
PREGNANCY

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or by visiting www.womensmentalhealth.org/preg.

Please see full Prescribing Information, including Boxed Warning, for complete information on Qelbree or visit www.QelbreeHCP.com.

REFERENCE: 1. Strattera [package insert]. Indianapolis, IN: Eli Lilly and Company.

Qelbree is a registered trademark of Supernus Pharmaceuticals, Inc. Rethink ADHD Symptom Control is a trademark of Supernus Pharmaceuticals, Inc.
©2022 Supernus Pharmaceuticals, Inc. All rights reserved. QBE.2022-0071 03/22

Lorem ipsum dolor sit amet, consectetur adipiscing elit.